Reteplase should not be used in patients having hypersensitivity to reteplase, polysorbate 80 or any of the other ingredients. Because thrombolytic therapy increases the risk of bleeding, Reteplase (MIREL) is contraindicated in the following situations: Active internal bleeding; History of cerebrovascular accident; Recent intracranial or intraspinal surgery or trauma; Intracranial neoplasm, arteriovenous malformation, or aneurysm; Known bleeding diathesis; Severe uncontrolled hypertension.